The stock of Vir Biotechnology Inc (VIR) has gone down by -2.81% for the week, with a -13.40% drop in the past month and a -7.80% drop in the past quarter. The volatility ratio for the week is 4.03%, and the volatility levels for the past 30 days are 4.10% for VIR. The simple moving average for the past 20 days is -7.62% for VIR’s stock, with a -18.86% simple moving average for the past 200 days.
Is It Worth Investing in Vir Biotechnology Inc (NASDAQ: VIR) Right Now?
VIR has 36-month beta value of 0.41. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VIR is 88.00M, and currently, short sellers hold a 6.17% ratio of that float. The average trading volume of VIR on April 04, 2024 was 1.09M shares.
VIR) stock’s latest price update
The stock of Vir Biotechnology Inc (NASDAQ: VIR) has increased by 0.73 when compared to last closing price of 9.62.Despite this, the company has seen a loss of -2.81% in its stock price over the last five trading days. InvestorPlace reported 2024-03-19 that Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
Analysts’ Opinion of VIR
Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR by listing it as a “Neutral.” The predicted price for VIR in the upcoming period, according to JP Morgan is $9 based on the research report published on January 29, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see VIR reach a price target of $14, previously predicting the price at $23. The rating they have provided for VIR stocks is “Neutral” according to the report published on September 08th, 2023.
JP Morgan gave a rating of “Overweight” to VIR, setting the target price at $34 in the report published on March 06th of the previous year.
VIR Trading at -4.86% from the 50-Day Moving Average
After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.74% of loss for the given period.
Volatility was left at 4.10%, however, over the last 30 days, the volatility rate increased by 4.03%, as shares sank -10.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.94% upper at present.
During the last 5 trading sessions, VIR fell by -2.81%, which changed the moving average for the period of 200-days by -62.70% in comparison to the 20-day moving average, which settled at $10.43. In addition, Vir Biotechnology Inc saw -3.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIR starting from HANLY ANN M., who sale 2,711 shares at the price of $10.05 back on Apr 01 ’24. After this action, HANLY ANN M. now owns 132,069 shares of Vir Biotechnology Inc, valued at $27,251 using the latest closing price.
Lee Sung, the EVP & Chief Financial Officer of Vir Biotechnology Inc, sale 6,008 shares at $9.89 during a trade that took place back on Mar 27 ’24, which means that Lee Sung is holding 100,492 shares at $59,404 based on the most recent closing price.
Stock Fundamentals for VIR
Current profitability levels for the company are sitting at:
- -14.19 for the present operating margin
- 0.84 for the gross margin
The net margin for Vir Biotechnology Inc stands at -13.18. The total capital return value is set at -0.37. Equity return is now at value -33.53, with -24.54 for asset returns.
Based on Vir Biotechnology Inc (VIR), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -6.25.
Currently, EBITDA for the company is -641.55 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 25.24. The receivables turnover for the company is 4.02for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.05.
Conclusion
To put it simply, Vir Biotechnology Inc (VIR) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
